Where does Taysha Gene Therapies, Inc.'s cash flow data come from?

Every line is extracted from Taysha Gene Therapies, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Net income	-$42.41M-97.0%	-$27.85M-48.3%	-$32.73M-28.2%	-$26.88M-28.4%	-$21.53M+10.5%
Depreciation and amortization	$295K+4.2%	$299K-1.6%	$200K-33.3%	$300K0.0%	$283K-12.9%
Stock-based compensation	$5.55M+68.4%	$3.53M+9.7%	$3.29M-2.1%	$3.19M-4.3%	$3.29M+3.0%
Change in accounts payable	$1.29M+39.7%	-$2.13M-41.4%	-$1.95M+48.5%	$3M+286%	$923K-76.8%
Change in other assets	$794K-24.5%	$2.14M+361%	-$971K-231%	——	$1.05M+51.8%
Other working capital changes	-$27K-640%	-$32K+55.6%	-$28K+95.9%	-$241K—	$5K+119%
Change in deferred revenue	——	-$5.49M-171%	$0+100%	-$1.99M-78.6%	-$2.3M+32.5%
Non-cash operating lease expense	$285K-15.9%	$400K+32.9%	$312K+5.1%	$308K+4.8%	$339K+4.3%
Net cash from operating activities	-$40.88M-85.6%	-$26.72M-46.0%	-$24.17M-11.8%	-$20.18M+6.1%	-$22.02M-11.2%
Capital expenditures	$24K-93.7%	$250K—	$108K+209%	$2K-99.0%	$378K+170%
Other investing activities	——	-$3K-9.1%	-$60K-2,082%	-$64K-2,227%	-$7K-155%
Acquired in-process research and development	$3M+694%	——	——	——	$378K+170%
Net cash from investing activities	-$3.02M-715%	-$247K—	-$48K-37.1%	——	-$371K-165%
Proceeds from issuance of common stock	$516K+588%	$1.02M—	$122K+771%	$0—	$75K+188%
Other financing activities	$19K+124%	-$90K—	-$285K-70.7%	$118K+1,008%	-$80K-167%
Payment of debt issuance costs	——	——	——	——	——
Net cash from financing activities	$711K+1,467%	$49.56M—	$8.8M+33.4%	$216.29M+207%	-$52K-136%
Net increase (decrease) in cash	-$43.19M-92.4%	$22.59M+221%	$0+100%	$196.17M+302%	-$22.44M-12.4%
Interest paid	$1.45M+11.8%	$1.45M+11.4%	$1.36M+2.9%	$1.29M-2.6%	$1.29M-2.6%
Depreciation	$295K+4.2%	$299K-1.6%	$200K-33.3%	$300K0.0%	$283K-12.9%
Increase Decrease In Accrued Expense And Other Liabilities	-$5.15M-142%	$2.67M—	$5.01M—	$732K+131%	-$2.13M-604%
Increase (Decrease) in Prepaid Expense and Other Assets	$794K-24.5%	$2.14M+361%	-$971K-231%	——	$1.05M+51.8%
Non Cash Change In Fair Value Of Term Loan	$32K-87.5%	$205K+128%	$186K-53.8%	$185K+981%	$256K+204%
Operating lease right-of-use asset amortization	$285K-15.9%	$400K+32.9%	$312K+5.1%	$308K+4.8%	$339K+4.3%
Other Noncash Income (Expense)	-$27K-640%	-$32K+55.6%	-$28K+95.9%	-$241K—	$5K+119%
Payment for (Proceeds from) Other Investing Activity	——	-$3K-9.1%	-$60K-2,082%	-$64K-2,227%	-$7K-155%
Payments to Acquire in Process Research and Development	$3M+694%	——	——	——	$378K+170%
Payment Of Shelf Registration Costs	——	——	——	——	$47K—
Proceeds From Issuance Of Common Stock Pursuant To At The Market Offering Net Of Sales Commissions And Other Offering Costs	——	$12.11M—	$12.11M—	$12.11M—	$12.11M—
Other, net	$19K+124%	-$90K—	-$285K-70.7%	$118K+1,008%	-$80K-167%
Proceeds from issuance of common stock relating to employee stock plans	$176K+135%	——	$84K+33.3%	——	$75K+188%
Accrued payables for capital expenditures	——	——	——	$388K+3,274%	$23K+100%
Fair Value Adjustment Of Warrants	——	$736K+987%	$292K—	$273K—	-$102K-130%
Proceeds From Issuance Of Warrants	——	$56.25K—	$56.25K—	$56.25K—	$56.25K—
Leased assets obtained in exchange for operating lease liabilities	——	$593.5K—	$593.5K—	$593.5K—	$593.5K—
Issuance of warrants	——	$409.25K—	$409.25K—	$409.25K—	$409.25K—
Free cash flow	-$40.9M-82.6%	-$26.97M-47.3%	-$24.27M-12.1%	-$20.18M+7.0%	-$22.4M-12.3%
Free cash flow	-$40.9M-82.6%	-$26.97M-47.3%	-$24.27M-12.1%	-$20.18M+7.0%	-$22.4M-12.3%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Taysha Gene Therapies, Inc.'s cash flow data come from?: Every line is extracted from Taysha Gene Therapies, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.